HCT Guidelines

Quickly access the latest clinical recommendations [1-7] from referral through post-transplant care including:

• Outcomes data and referral timing for 16 diseases
• Long-term screening tests/procedures/vaccinations
• Chronic GVHD screening by area of the body

Download the app 

Be The Match Patient Services offers a patient-friendly version of the post-transplant screening guidelines. Patients can use these guidelines to understand and prepare for follow up care appointments. Learn more about the free mobile app, online and print versions of these patient guidelines >

References

The guidelines are based on published research and the collaboration of leading transplant organizations:

1. Evidence-based Reviews, developed by the American Society for Blood and Marrow Transplantation, 2003-2011. Published in Biology of Blood and Marrow Transplantation and available online at http://asbmt.org/displaycommon.cfm?an=4.   

2. Majhail NS, Rizzo JD, Lee SJ, et al. Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation; Center for International Blood and Marrow Transplant Research (CIBMTR), American Society for Blood and Marrow Transplantation (ASBMT), European Group for Blood and Marrow Transplantation (EBMT), Asia-Pacific Blood and Marrow Transplantation Group (APBMT), Bone Marrow Transplant Society of Australia and New Zealand (BMTSANZ), East Mediterranean Blood and Marrow Transplantation Group (EMBMT) and Sociedade Brasileira de Transplante de Medula Ossea (SBTMO). Co-published in Biol Blood Marrow Transplant, 2012; 18(3): 348-371; Bone Marrow Transplant, 2012; 47(3): 337–341; and Hematol Oncol Stem Cell Ther, 2012; 5(1): 1-30.  

3. Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. Diagnosis and Staging Working Group Report. Biol Blood Marrow Transplant. 2005; 11(12): 945-956. http://www.bbmt.org/article/PIIS1083879105006312/fulltext 

4. Mitchell, S.A. and Pavletic, S.Z., Measuring the therapeutic response in chronic GVHD trials: An instructional manual [CD]. Silver Spring, Md.: Palladian Partners; 2006.

5. These guidelines have been developed by the NMDP in consultation with Sandra A. Mitchell, CRNP, MScN, AOCN; National Institutes of Health Clinical Center; and Steven Z. Pavletic, M.D.; National Cancer Institute, National Institutes of Health, Bethesda, Md. The information in this document does not represent the official position of the NIH or the U.S. Government.
   
   Additional Review from: Dennis L. Confer, M.D., National Marrow Donor Program, Minneapolis, Minn. Corey Cutler, M.D., Dana-Farber Cancer Institute, Boston, Mass. Stephanie J. Lee, M.D., Fred Hutchinson Cancer Research Center, Seattle, Wash.
   
   Text and tables adapted from reports of the NIH Consensus Development Project on Criteria for Clinical Trials in Chronic GVHD with permission from Biology of Blood and Marrow Transplantation and its publisher ASBMT.

6. Tomblyn M, Chiller T, Einsele H, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant. 2009; 15(10): 1143-1238.
   http://www.bbmt.org/article/S1083-8791(09)00300-0/fulltext 

7. Ljungman P, Cordonnier C, Einsele H, et al. Vaccination of hematopoietic cell transplant recipients. Bone Marrow Transplant. 2009; 44(8): 521-526. http://www.nature.com/bmt/journal/v44/n8/full/bmt2009263a.html